Scarica l'app Stockscreener
62.88
3.68%
2.23
Dopo l'orario di chiusura:
62.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$60.65
Aprire:
$60.55
Volume 24 ore:
1.14M
Relative Volume:
0.91
Capitalizzazione di mercato:
$5.00B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-10.59
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
+3.15%
1M Prestazione:
+26.27%
6M Prestazione:
+13.36%
1 anno Prestazione:
+77.23%
Intervallo 1D:
$59.20
$63.19
Intervallo di 1 settimana:
$58.87
$63.19
Portata 52W:
$34.57
$63.19
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
62.88 | 4.82B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.11 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.71 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.17 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
731.77 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.89 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Will PTC Therapeutics Inc benefit from government policyMarket Volume Report & Low Risk Entry Point Tips - خودرو بانک
Gastroparesis Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - The Globe and Mail
Ellsworth Advisors LLC Purchases Shares of 11,529 PTC Therapeutics, Inc. $PTCT - MarketBeat
Harbor Capital Advisors Inc. Grows Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Jobs Data: Will PTC Therapeutics Inc. benefit from geopolitical trendsInflation Watch & Step-by-Step Trade Execution Guides - خودرو بانک
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $3.07 Million Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Director Emma Reeve Sells 15,705 Shares - MarketBeat
Using data filters to optimize entry into PTC Therapeutics Inc.Layoff News & Safe Entry Point Alerts - newser.com
Intech Investment Management LLC Buys 15,167 Shares of PTC Therapeutics, Inc. $PTCT - Defense World
PTC Therapeutics, Inc. $PTCT Shares Acquired by Acadian Asset Management LLC - Defense World
PTC Therapeutics, Inc. $PTCT Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells 12,000 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Sets New 12-Month HighTime to Buy? - MarketBeat
Market Moves: Is PTC Therapeutics Inc. a stock for growth or value investorsJuly 2025 Recap & AI Based Buy and Sell Signals - خودرو بانک
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 24,585 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) VP Sells $1,382,504.00 in Stock - MarketBeat
Death Cross: Will Heidrick & Struggles International Inc. announce a stock splitWeekly Market Report & Daily Stock Trend Watchlist - خودرو بانک
Recap Report: Is PTC Therapeutics Inc. stock a good dividend stockJuly 2025 Volume & Daily Risk Controlled Trade Plans - خودرو بانک
Bond Watch: What is PTC Therapeutics Incs valuation compared to sectorJuly 2025 PreEarnings & Precise Buy Zone Tips - خودرو بانک
Bayforest Capital Ltd Makes New Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Sells $2,268,262.00 in Stock - MarketBeat
Multi factor analysis applied to PTC Therapeutics Inc.July 2025 Pullbacks & Free Growth Oriented Trading Recommendations - newser.com
AQR Capital Management LLC Grows Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Can PTC Therapeutics' (PTCT) New PKU Partnership Reveal Its Long-Term Rare Disease Strategy? - Sahm
Can PTC Therapeutics Inc. stock continue upward trendJuly 2025 Trends & Smart Money Movement Alerts - baoquankhu1.vn
Ptc Therapeutics stock hits 52-week high at 61.17 USD - Investing.com
PTC Therapeutics, Inc. $PTCT Shares Acquired by Parkman Healthcare Partners LLC - MarketBeat
Insider Sell: David Southwell Sells 12,000 Shares of PTC Therape - GuruFocus
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU - Insider Monkey
Adage Capital Partners GP L.L.C. Has $30.32 Million Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Insider Sell Alert: Eric Pauwels Sells 39,850 Shares of PTC Ther - GuruFocus
How sensitive is PTC Therapeutics Inc. to inflationJuly 2025 Recap & AI Based Buy and Sell Signals - Lancaster City Council
Bank of America Securities Keeps Their Buy Rating on PTC Therapeutics (PTCT) - The Globe and Mail
Canada Pension Plan Investment Board Raises Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
PTC Therapeutics at Morgan Stanley Conference: Strategic Insights and Updates - Investing.com Canada
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $76 - 富途牛牛
Can PTC Therapeutics Inc. Overcome Bearish Sentiment2025 Short Interest & Technical Entry and Exit Tips - beatles.ru
Volume Surge May Signal Institutional Interest in PTC Therapeutics Inc.Trade Ideas & AI Enhanced Trade Execution Alerts - beatles.ru
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Shares Bounce 26% But Its Business Still Trails The Industry - simplywall.st
PTC Therapeutics (NASDAQ:PTCT) Director Sells $83,600.05 in Stock - MarketBeat
PDT Partners LLC Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.25%
0.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):